Choosing Comparators for HTA: Why the Right Standard of Care Differs by Country

The comparator is the most consequential choice in a value dossier. A strong result against the wrong comparator is, to a payer, no result at all.

Why one trial rarely fits every market

Registration trials are usually designed to satisfy regulators, often using a placebo, an add-on design or a comparator that is acceptable across several regions. HTA bodies ask something narrower: how does the product compare with the treatment their own patients would otherwise receive? Standard of care varies between countries because of guideline differences, reimbursement status, availability and local practice.

What payers generally expect

  • A comparator that reflects routine local practice, not only what was convenient in the trial.
  • Evidence on relevant patient subgroups, because the best alternative can differ within one indication.
  • A clear rationale when the comparator used is not the one the payer would choose.

The joint clinical assessment changes the mechanics

Under the EU HTA Regulation, the scope of a joint clinical assessment is set through a PICO process: population, intervention, comparator and outcomes. Participating Member States state their needs, and the assessors consolidate them, aiming for the fewest PICOs that still meet those needs. The developer supplies information on the product and indication, but does not propose the PICOs itself. Comparators may include treatments used off-label in the EU, or non-drug interventions such as surgery.

The practical consequence is that several comparators may be requested for one population, and a single trial rarely covers all of them. Your evidence plan needs to anticipate this long before the scope is issued.

What to do in practice

  • Map likely comparators in each priority market while the pivotal programme is still being designed.
  • Identify which comparisons will need indirect evidence, and plan the analyses to support them.
  • Use scientific advice, including joint scientific consultations where eligible, to test the design against both regulatory and HTA expectations.
  • Keep a living comparator map and revisit it as guidelines and reimbursement lists change.

Treat the gap as a plan, not a surprise

If the registration trial does not match a payer’s comparator, that is rarely fatal. It is a gap to be bridged with transparent methods and honest assumptions, which is far easier when it is planned than when it is discovered at submission.

A short checklist

  • Which comparators will each priority market probably expect, and on what basis?
  • Which of these does the pivotal evidence cover directly?
  • For the rest, what indirect or supportive evidence is planned?
  • When will the plan next be reviewed against changes in guidelines and reimbursement lists?

Teams that can answer these questions before submission tend to discover their evidence gaps while there is still time to act on them.

How PQRA helps

PQRA helps teams reconcile regulatory strategy with HTA requirements: mapping comparator expectations across target markets, flagging where the evidence plan leaves gaps, and preparing questions for scientific advice. Analytical work such as indirect comparisons sits with your HEOR specialists, and we work alongside them.

Ready to discuss your market access plan? Contact PQRA to talk through your product and your target markets.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *